Nodo-paranodopatie s protilátkami IgG4 proti neurofascinu-155

Czech version

Authors: K. Revendová ^1,2; O. Volný ^1,2; J. Junkerová ^1,2; I. Woznicová ²; J. Slonková ^1,2; R. Mazanec ³; M. Bar ^1,2
Authors‘ workplace: Katedra a centrum klinických neurověd, LF OU, Ostrava ¹; Neurologická klinika FN Ostrava ²; Neuromuskulární centrum, 2. LF UK a FN Motol, Praha ³
Published in: Cesk Slov Neurol N 2021; 84(6): 567-569
Category: Letters to Editor
doi: https://doi.org/10.48095/cccsnn2021567

Sources

1. Van den Bergh PYK, Doorn PA, Hadden RDM et al. European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force – Second revision. J Peripher Nerv Syst 2021; 26 (3): 242–268. doi: 10.1111/jns.12455.

2. Van den Bergh PYK, van Doorn PA, Jacobs BC et al. Boundaries of chronic inflammatory demyelinating polyradiculoneuropathy. J Peripher Nerv Syst 2020; 25 (1): 4-8. doi: 10.1111/jns.12364.

3. Van Den Bergh PYK, Hadden RDM, Bouche P et al. European federation of neurological societies/peripheral nerve society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripher. Eur J Neurol 2010; 17 (3): 356–363. doi: 10.1111/j.1468-1331.2009.02 930.x.

4. Lehmann HC, Burke D, Kuwabara S. Chronic inflammatory demyelinating polyneuropathy: update on diagnosis, immunopathogenesis and treatment. J Neurol Neurosurg Psychiatry 2019; 90 (9): 981–987. doi: 10.1136/jnnp-2019-320314.

5. Kira JI, Yamasaki R, Ogata H. Anti-neurofascin autoantibody and demyelination. Neurochem Int 2019; 130: 104360. doi: 10.1016/j.neuint.2018.12.011.

6. Garg N, Park SB, Yiannikas C et al. Neurofascin-155 IGG4 neuropathy: pathophysiological insights, spectrum of clinical severity and response to treatment. Muscle Nerve 2018; 57 (5): 848–851. doi: 10.1002/mus. 26010.

7. Ogata H, Yamasaki R, Hiwatashi A et al. Characterization of IgG4 anti-neurofascin 155 antibody-positive polyneuropathy. Ann Clin Transl Neurol 2015; 2 (10): 960–971. doi: 10.1002/acn3.248.

8. Devaux JJ, Miura Y, Fukami Y et al. Neurofascin-155 IgG4 in chronic inflammatory demyelinating polyneuropathy. Neurology 2016; 6 (9): 800–807. doi: 10.1212/WNL.0000000000002418.

9. Shimizu S, Iijima M, Fukami Y et al. Efficacy and safety of rituximab in refractory CIDP with or without IgG4 autoantibodies (RECIPE): protocol for a double-blind, randomized, placebo-controlled clinical trial. JMIR Res Protoc 2020; 9 (4): e17117. doi: 10.2196/17117.

10. Breiner A, Barnett C, Bril V. INCAT disability score: a critical analysis of its measurement properties. Muscle Nerve 2014; 50 (2): 164–169. doi: 10.1002/mus.24207.